知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

181 records (took 0.054 seconds)

    N-(4-HYDROXY-4-METHYL-CYCLOHEXYL)-4-PHENYL-BENZENESULFONAMIDE AND N-(4-HYDROXY-4-METHYL-CYCLOHEXYL)-4-(2-PYRIDYL)-BENZENESULFONAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE
    2.
    发明申请
    N-(4-HYDROXY-4-METHYL-CYCLOHEXYL)-4-PHENYL-BENZENESULFONAMIDE AND N-(4-HYDROXY-4-METHYL-CYCLOHEXYL)-4-(2-PYRIDYL)-BENZENESULFONAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE 审中-公开

    公开(公告)号：US20180297955A1

    公开(公告)日：2018-10-18

    申请号：US16011718

    申请日：2018-06-19

    Applicant: PIMCO 2664 LIMITED

    Inventor： Stephen Allan Smith ,  Lisa Patel ,  Iain Robert Greig

    IPC: C07D213/85 ,  C07C311/20

    Abstract: The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain substituted N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and N-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamide compounds (collectively referred to herein as HMC compounds) that are useful, for example, in the treatment of disorders (e.g., diseases) including, inflammation and/or joint destruction and/or bone loss; disorders mediated by excessive and/or inappropriate and/or prolonged activation of the immune system; inflammatory and autoimmune disorders, for example, rheumatoid arthritis; psoriasis; psoriatic arthritis; chronic obstructive pulmonary disease (COPD); asthma; atherosclerosis; inflammatory bowel disease; ankylosing spondylitis; multiple sclerosis; systemic lupus erythematosus; Sjogren's syndrome; a disorder associated with bone loss, such as bone loss associated with excessive osteoclast activity in rheumatoid arthritis, osteoporosis, cancer-associated bone disease, or Paget's disease; cancer, such as a haematological malignancy, such as multiple myeloma, leukemia, or lymphoma, or a solid tumour cancer, such as bladder cancer, breast cancer (female and/or male), colon cancer, renal cell carcinoma, kidney cancer, lung cancer, pancreatic cancer, gastric cancer, prostate cancer, brain cancer, skin cancer, thyroid cancer, basal cell ameloblastoma, or melanoma; a disorder associated with fibrosis, such as systemic sclerosis or scleroderma; or a rare vasculitide, such as Behçet's disease. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, for example, in therapy.

    N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamides and N-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamides and their therapeutic use
    5.
    发明授权
    N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamides and N-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamides and their therapeutic use 有权

    公开(公告)号：US09624167B2

    公开(公告)日：2017-04-18

    申请号：US14899422

    申请日：2014-06-24

    Applicant: PIMCO 2664 LIMITED

    Inventor： Lisa Patel ,  Stephen Allan Smith ,  Iain Robert Greig ,  Samuel Cameron Williams

    IPC: C07C311/20 ,  C07D213/61

    CPC classification number: C07C311/20 ,  C07C2101/14 ,  C07C2601/14 ,  C07D213/61

    Abstract: The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain substituted N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and N-(4-hydroxy-4-methyl -cyclohexyl)-4-(2-pyridyl)benzenesulfonamide compounds (collectively referred to herein as HMC compounds) that are useful, for example, in the treatment of disorders (e.g., diseases) including, inflammation and/or joint destruction and/or bone loss; disorders mediated by excessive and/or inappropriate and/or prolonged activation of the immune system; inflammatory and autoimmune disorders, for example, rheumatoid arthritis; psoriasis; psoriatic arthritis; chronic obstructive pulmonary disease (COPD); asthma; atherosclerosis; inflammatory bowel disease; ankylosing spondylitis; multiple sclerosis; systemic lupus erythematosus; Sjogren's syndrome; a disorder associated with bone loss, such as bone loss associated with excessive osteoclast activity in rheumatoid arthritis, osteoporosis, cancer-associated bone disease, or Paget's disease; cancer, such as a haematological malignancy, such as multiple myeloma, leukemia, or lymphoma, or a solid tumour cancer, such as bladder cancer, breast cancer (female and/or male), colon cancer, renal cell carcinoma, kidney cancer, lung cancer, pancreatic cancer, gastric cancer, prostate cancer, brain cancer, skin cancer, thyroid cancer, basal cell ameloblastoma, or melanoma; a disorder associated with fibrosis, such as systemic sclerosis or scleroderma; or a rare vasculitide, such as Behçet's disease. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, for example, in therapy.

    Pharmaceutical composition with enhanced efficacy for inhibiting angiogenesis
    6.
    发明授权
    Pharmaceutical composition with enhanced efficacy for inhibiting angiogenesis 有权
    具有增强抑制血管发生功效的药物组合物

    公开(公告)号：US09371286B2

    公开(公告)日：2016-06-21

    申请号：US14232598

    申请日：2011-05-23

    Applicant: Ho Jeong Kwon ,  Gyoon Hee Han ,  Hye Jin Jung ,  Jeong Jea Seo

    Inventor： Ho Jeong Kwon ,  Gyoon Hee Han ,  Hye Jin Jung ,  Jeong Jea Seo

    IPC: C07D215/38 ,  C07C311/21 ,  C07C311/20

    CPC classification number: C07D215/38 ,  C07C311/20 ,  C07C311/21 ,  C07C2601/14

    Abstract: The present invention relates to a pharmaceutical composition for inhibiting angiogenesis and a novel sulfonyl amide derivative compound which can be useful for the prevention or treatment of angiogenesis-related diseases or disorders. Since the compound used as an active ingredient in the pharmaceutical composition of the invention is specifically bound to UQCRB and inhibits biological functions thereof, apoptosis is not induced and angiogenic responses are inhibited. Therefore, the compound used as an active ingredient in the pharmaceutical composition of the invention can be useful as an effective and safe angiogenesis inhibitory agent.

    Abstract translation: 本发明涉及一种抑制血管发生的药物组合物和一种可用于预防或治疗血管生成相关疾病或病症的新型磺酰基酰胺衍生物化合物。 由于用作本发明的药物组合物中的活性成分的化合物与UQCRB特异性结合并抑制其生物学功能，因此不诱导细胞凋亡并且抑制血管生成反应。 因此，本发明的药物组合物中作为活性成分使用的化合物可用作有效且安全的血管生成抑制剂。

Patent Agency Ranking